In vitro activities of daptomycin, vancomycin, quinupristin-dalfopristin, linezolid, and five other antimicrobials against 307 gram-positive anaerobic and 31 Corynebacterium clinical isolates

Antimicrobial Agents and Chemotherapy

Volumn 47, Issue 1, 2003, Pages 337-341

  Goldstein, Ellie J C ^a   Citron, Diane M ^a   Merriam, C Vreni ^a   Warren, Yumi A ^a   Tyrrell, Kerrin L ^a   Fernandez, Helen T ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; ANTIBIOTIC AGENT; CALCIUM; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; IMIPENEM; LINEZOLID; PENICILLIN DERIVATIVE; PIPERACILLIN PLUS TAZOBACTAM; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIUM ISOLATE; COLONY FORMING UNIT; CONTROLLED STUDY; CORYNEBACTERIUM; GRAM POSITIVE BACTERIUM; GROWTH INHIBITION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STRAIN DIFFERENCE;

EID: 0037224432     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.47.1.337-341.2003     Document Type: Article

References (24)

1. Alborn, W. E., Jr., N. E. Allen, and D. A. Preston. 1991. Daptomycin disrupts membrane potential in growing Staphylococcus aureus. Antimicrob. Agents Chemother. 35:2282-2287.
2. Alexander, C. J., J. S. Brazier, D. M. Citron, and E. J. C. Goldstein. 1995. Identification methods and antimicrobial resistance patterns of clinical isolates of Clostridium clostridioforme, Clostridium innocuum, and Clostridium ramosum compared to Clostridium perfringens. J. Clin. Microbiol. 33:3209-3215.
3. Barry, A. L., P. C. Fuchs, and S. D. Brown. 2001. In vitro activity of daptomycin against 2,789 clinical isolates from 11 North American medical centers. Antimicrob. Agents Chemother. 45:1919-1922.
4. Bartoloni, A., M. G. Colao, A. Orsi, R. Dei, E. Giganti, and F. Parenti. 1990. In vitro activity of vancomycin, teichoplanin, daptomycin, ramoplanin, MDL 62873 and other agents against staphylococci, enetrococci, and Clostridium difficile. J. Antimicrob. Chemother. 26:627-633.
5. Brazier, J. S., W. Fawley, J. Freeman, and M. H. Wilcox. 2001. Reduced susceptibility of Clostridium difficile to metronidazole. J. Antimicrob. Chemother. 48:741-742.
6. Chow, A. W., and N. Cheng. 1988. In vitro activity of daptomycin (LY146032) and paldimycin (U-70,138F) against anaerobic gram-positive bacteria. Antimicrob. Agents Chemother. 32:788-790.
7. Dong, M. Y., T. W. Chang, and S. L. Gorbach. 1987. Treatment of Clostridium difficile colitis in hamsters with a lipopeptide antibiotic, LY 146032. Antimicrob. Agents Chemother. 31:1135-1136.
8. Eliopoulos, G. M., S. Wiley, E. Reiszner, P. G. Spitzer, G. Caputo, and R. C. Moellering, Jr. 1986. In vitro and in vivo activity of LY 146032, a new cyclic lipopeptide antibiotic. Antimicrob. Agents Chemother. 30:532-535.
9. Faruki, H., A. C. Niles, R. L. Heeren, and P. R. Murray. 1987. Effect of calcium on the in vitro activity of LY 146032 against Clostridium difficile. Antimicrob. Agents Chemother. 31:461-462.
10. Fuchs, P. C., A. L. Barry, and S. D. Brown. 2000. Daptomycin susceptibility tests: interpretive criteria, quality control, and effect of calcium on in vitro tests. Diagn. Microbiol. Infect. Dis. 38:51-58.
11. Greenwood, D., and J. Palfreyman. 1987. Comparative activity of LY146032 against anaerobic cocci. Eur. J. Clin. Microbiol. 6:682-684.
12. Hospital Infection Control Practice Advisory Committee. 1995. Recommendations for preventing the spread of vancomycin resistance. Infect. Control Hosp. Epidemiol. 16:105-113.
13. Huovinen, P., and P. Kotilainen. 1987. In vitro activity of a new cyclic lipopeptide antibiotic, LY146032, against gram-positive clinical bacteria. Antimicrob. Agents Chemother. 31:455-457.
14. Jones, R. N. 1989. Effects of reduced cation supplementation recommendations (National Committee for Clinical Laboratory Standards) on daptomycin antistaphylococcal activity. Antimicrob. Agents Chemother. 33:1652-1653.
15. Jones, R. N., and A. L. Barry. 1987. Antimicrobial activity and spectrum of LY146032, a lipopeptide antibiotic, including susceptibility testing recommendations. Antimicrob. Agents Chemother. 31:625-629.
16. Murray, P. R., E. J. Baron, M. A. Pfaller, F. C. Tenover, and R. H. Yolken (ed.). 1999. Manual of clinical microbiology, 7th ed. American Society for Microbiology, Washington, D.C.
17. National Committee for Clinical Laboratory Standards. 2000. Method for dilution antimicrobial susceptibility testing for bacteria that grow aerobically, 5th ed. Approved standard. NCCLS publication M7-A5. National Committee for Clinical Laboratory Standards, Wayne, Pa.
18. National Committee for Clinical Laboratory Standards. 2001. Methods for antimicrobial susceptibility testing of anaerobic bacteria, 5th ed. Approved standard. NCCLS publication M11-A5. National Committee for Clinical Laboratory Standards, Wayne, Pa.
19. Nord, C. E., A. Lindmark, and I. Persson. 1987. Susceptibility of Clostridium difficile to LY146032. Eur. J. Clin. Microbiol. 6:189.
20. Nord, C. E., A. Lindmark, and I. Persson. 1987. LY146032 treatment of Clostridium difficile colitis in hamsters. Eur. J. Clin. Microbiol. 6:686.
21. Silva, M., N. V. Jacobus, and S. L. Gorbach. 1988. In vitro activity of LY 146032 against gram-positive bacteria. Diagn. Microbiol. Infect. Dis. 9:79-85.
22. Silverman, J. A., N. Oliver, T. Andrew, and T. Li. 2001. Resistance studies with daptomycin. Antimicrob. Agents Chemother. 45:1799-1802.
23. Summanen, P., E. J. Baron, D. M. Citron, C. A. Strong, H. M. Wexler, and S. M. Finegold. 1993. Wadsworth anaerobic bacteriology manual, 5th ed. Star Publishing Co., Belmont, Calif.
24. Tally, F. P., and M. F. DeBruin. 2000. Development of daptomycin for gram-positive infections. J. Antimicrob. Chemother. 46:523-526.